Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › UBT251 phase 2 (obesity)

UBT251 phase 2 (obesity)

UBT251 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
UBT251
Population
obesity
Phase
2
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
UBT251 4.0 mg (start 1.0 mg)obesity china24———−19.7 % vs −2.0 %
estimand not specified
———————verified
UBT251 6.0 mgobesity china24———−18.7 % vs −2.0 %
estimand not specified
———————verified
UBT251 2.0 mgobesity china24———−13.6 % vs −2.0 %
estimand not specified
———————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (3)
  • UBT251 4.0 mg (start 1.0 mg) · weight_unsp · Results
    LSM percentage change in weight
  • UBT251 6.0 mg · weight_unsp · Results
    LSM percentage change in weight
  • UBT251 2.0 mg · weight_unsp · Results
    LSM percentage change in weight

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.